The clinical spectrum of Fontan-associated liver disease: results from a prospective multimodality screening cohort by Munsterman, I.D. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The clinical spectrum of Fontan-associated liver disease: results
from a prospective multimodality screening cohort
Citation for published version:
Munsterman, ID, Duijnhouwer, AL, Kendall, T, Bronkhorst, CM, Ronot, M, van Wettere, M, van Dijk, APJ,
Drenth, JPH & Tjwa, ETTL 2019, 'The clinical spectrum of Fontan-associated liver disease: results from a
prospective multimodality screening cohort', European Heart Journal, vol. 39, no. 2, pp. 353-360.
https://doi.org/10.1093/eurheartj/ehy620
Digital Object Identifier (DOI):
10.1093/eurheartj/ehy620
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
European Heart Journal
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 12. Sep. 2019
1 
 
Title: The clinical spectrum of Fontan-Associated Liver Disease: results from a prospective 
multimodality screening cohort.  
Authors: I.D. Munsterman1, A.L. Duijnhouwer2, T.J. Kendall3, C.M. Bronkhorst4, M. Ronot5, M. van 
Wettere5, A.P.J. van Dijk2, J.P.H. Drenth1, E.T.T.L. Tjwa1  
On behalf of the Nijmegen Fontan Initiative (A.P.J. van Dijk2, J.P.H. Drenth1, A.L. Duijnhouwer2, R.R.J. 
van Kimmenade2, S.W. van Koeverden6, I.D. Munsterman1, R.B. Tanke7, E.T.T.L. Tjwa1, F.E.A. Udink 
ten Cate7) 
Affiliations:  
1. Department of Gastroenterology and Hepatology, Radboud university medical centre, Nijmegen, 
the Netherlands  
2. Department of Cardiology, Radboud university medical centre, Nijmegen, the Netherlands 
3. Division of Pathology, University of Edinburgh, United Kingdom 
4. Department of Pathology, Jeroen Bosch Hospital, ‘s-Hertogenbosch, the Netherlands 
5. Department of Radiology, University Hospitals Paris Nord Val de Seine, Beaujon , Clichy, France 
6. Department of Radiology, Radboud university medical centre, Nijmegen, the Netherlands  
7. Department of Pediatric Cardiology, Radboud university medical centre, Nijmegen, the 
Netherlands  
Corresponding author 
Eric Tjwa, MD PhD 
Dept. of Gastroenterology and Hepatology 
Radboud university medical center 
Postbus 9101, 6500 HB Nijmegen  
Geert-Grooteplein Zuid 10 (route 455) 
The Netherlands 
Email: eric.tjwa@radboudumc.nl 
 
 
 
 
 
2 
 
Abstract 
Aims 
Liver fibrosis and cirrhosis are a consequence of a Fontan physiology, and determine prognosis. It is 
unclear whether non-invasive assessment of  liver pathology is helpful to provide clinically relevant 
information. The aims of this study were to assess the spectrum of Fontan-associated liver disease 
(FALD) and usefulness of non-invasive methods to assess biopsy confirmed liver fibrosis.   
Methods  
Hepatic screening of consecutive patients consisted of a blood panel, ultrasonography, elastography, 
contrast-enhanced MRI/CT, and liver biopsy (scored with Fontan specific fibrosis scores and collagen 
proportionate area; CPA). Fibrosis parameters, varices, ascites, and splenomegaly were measured on 
imaging.  
Results 
38/49 referred patients (27 ± 6.6 years, 73.7% male) underwent the complete screening protocol. 
Liver fibrosis on biopsy was present in all patients, and classified as severe (stage 3-4) in 68%. Median 
CPA was 22.5% (16.9-29.5) and correlated with individual fibrosis scores. ELF® and liver stiffness were 
elevated, but MELD-XI scores were low in all patients. Fibrosis severity neither correlated to ELF® and 
liver stiffness, nor to (semi-) quantitative fibrosis parameters on MRI/CT. Varices were present in 50% 
and hyper-enhancing nodules in 25% of patients, both independent of fibrosis stage, but varices 
were associated with higher CPA values. 
Conclusion 
The FALD spectrum includes both hepatic congestion and severe fibrosis, with signs of portal 
hypertension and hyper-enhancing nodules as significant manifestations. Routine imaging, transient 
elastography and serum biomarkers are unable to accurately assess severity of liver fibrosis in this 
cohort. Future research should focus on validating new diagnostic tools with biopsy as the reference 
standard.  
Keywords (6): Fontan, Fontan-associated liver disease, liver fibrosis/cirrhosis, , liver biopsy, screening, 
nodules 
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Introduction  
Structural hepatic changes are a recognized complication after palliative Fontan surgery of patients 
with severe congenital heart disease.1, 2 The Fontan procedure establishes a unique hemodynamic 
physiology, resulting from a direct conduit between caval veins and pulmonary arteries.3, 4 As a 
consequence, caval pressure rises resulting in elevated hepatic afterload, liver congestion, and 
increased risk of liver fibrosis.5  
Multidisciplinary consensus recommends hepatological evaluation of patients for Fontan-associated 
liver disease (FALD), however specific guidelines how to commence screening are lacking.8 Since liver 
fibrosis is mostly asymptomatic, clinical history and physical examination are of limited value. As in 
many other chronic liver diseases routine liver biochemistry is inaccurate to quantify Fontan-
associated liver fibrosis.9-11 Several non-invasive tools, such as transient elastography and fibrosis 
biomarkers have gained traction to diagnose and quantify fibrosis, but have only been evaluated to a 
limited extent in this population.12-14 A liver biopsy is considered to be the gold standard for staging 
of hepatic fibrosis, and is used as the reference standard method in evaluations of biomarkers and 
non-invasive markers of liver fibrosis. However, biopsies are invasive and carry a certain risk of 
complications, in particular bleeding.16 The exact bleeding risk is unknown, but could be high in the 
Fontan population in view of the frequent use of anticoagulants.17 There are a number of studies that 
have evaluated the extent of liver disease in this population but they are hampered by retrospective 
design, selection bias, or the absence of histology as reference standard.7, 12-14, 18-24  It is unclear which 
investigations contribute to  true prognostic information that changes clinical management and 
outcomes.  
The aims of this study were (1) to assess the clinical spectrum of FALD including signs of portal 
hypertension and hepatic nodules in asymptomatic patients with a Fontan physiology, and (2) to 
examine the usefulness of serum and image-based fibrosis markers to assess fibrosis, in comparison 
to liver biopsy as the reference standard.   
 
Methods  
Study population 
All consecutive patients (18 years or older) with a Fontan physiology, monitored at the congenital 
cardiology department of the Radboud university medical centre were referred to the hepatology 
department for  a prospective screening programme for liver disease. Inclusion took place from 
November 2015 to September 2017. The screening protocol consisted of routine biochemistry 
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testing, VO2max exercise test, cardiac and liver ultrasound, transient elastography, advanced imaging 
of the liver with MRI or CT, and liver biopsy. Patients were required to consent for the individual 
procedures. All procedures were performed on the same day, while the liver biopsy procedure and 
advanced imaging were performed within a range of three months. Data from clinical evaluations 
was collected through chart review. The study was approved by the institutional review board of the 
Radboud university medical centre (no. 2015-2132).  
Clinical evaluation  
All patients were simultaneously clinically evaluated at the departments of Hepatology and 
Cardiology. Patients were evaluated for risk factors for liver disease such as alcohol and drug use. 
Physical examination included hemodynamic parameters and signs of Fontan failure or liver disease  
such as peripheral edema, ascites, spider naevi, palmar erythema, and jaundice. Patients underwent 
cardiac ultrasonography, visually assessing global ventricle function, and a VO2 max test. 25, 26  
Liver biopsy and histological assessment  
Ultra-sound guided percutaneous liver biopsy (16G, true-cut or suction biopsy) was performed under 
conscious sedation by experienced hepatologists (ET, JD). Liver tissue slides were stained with 
hematoxylin-eosin, elastica-Van Gieson, and picrosirius red. Slides were evaluated independently by 
two liver pathologists experienced in vascular liver disease (CB, TK). Adequate biopsy samples were 
defined as length ≥ 2cm and the presence of ≥ 11 portal tracts. Three fibrosis scores, previously 
reported to assess Fontan-associated liver fibrosis, were assessed: Gross architectural distortion 
score,19 scoring overall fibrosis distribution and architectural changes (ranging 0-4); A four 
component score,20 scoring portal fibrosis (0-4), sinusoidal fibrosis (0-4), sinusoidal dilation (0-3), 
portal inflammation (0-3); and the congestive heart failure fibrosis score (CHFS; 0-4).27 See 
supplementary files for exact description of scores.  
To obtain a comprehensive overview of total amount of fibrosis present, the percentage of total 
tissue area occupied by collagen (picrosirius red stain) or so-called collagen proportionate area (CPA) 
was calculated, as described before.28 Steatosis was assessed with NAFLD activity score (0-3).29 
Laboratory evaluation 
Laboratory testing included routine liver biochemistry (alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphotase (ALP), gamma-glutamyl transferase (GGT), total 
bilirubin, and liver function tests (INR or prothrombin time, platelets, and albumin). Hepatitis B and C 
serology was tested. A commercial panel of direct fibrosis markers was assessed (Enhanced Liver 
Fibrosis Test®, Siemens, the Netherlands) consisting of hyaluronic acid, PIIINP, and TIMP-1. The score 
has a cut-off of ≥ 7.7 for the presence of fibrosis.30 Furthermore the APRI, an indirect fibrosis score 
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was calculated from AST and platelets.31 Von Willebrand factor (vWf) and VITRO score (VWF/platelet 
ratio), as surrogate markers for portal hypertension, were measured.32, 33 MELD-XI score (developed 
to assess end-stage liver disease in patients on anticoagulants by excluding INR) was calculated.34  
Liver ultrasonography and transient elastography  
Dedicated liver ultrasonography (Hitachi Preius TM) was performed, and evaluation focused on 
aspect, pattern of parenchyma and liver surface, assessment of focal lesions, presence of ascites, and 
spleen size. Standardized Doppler flow measurements were performed on inferior caval vein 
(diameter, respiratory variability), hepatic veins (diameter, flow pattern), portal vein (flow direction 
and flow velocity), and hepatic artery (peak systolic flow velocity, end diastolic flow velocity, and 
resistance index). 
Liver stiffness (in kPa) was measured by transient elastography with Fibroscan 502®, assessing the 
median of ≥10 measurements with an interquartile range/median ≤ 30%.  
Spleen diameter (mm) and platelet count were incorporated in the platelet/spleen ratio, with a 
proposed cut-off of <909 for identification of patients at risk for presence of clinically relevant portal 
hypertension.35 
Advanced imaging  
A contrast-enhanced MRI was performed (Dotarem®; gadoterate meglumine contrast, Siemens, 3 
tesla), or in case this was not possible a multiphase liver CT-scan (iodinated contrast, Toshiba, slide 
thickness 5 mm). For clinical CT and MRI protocols see supplementary methods. Liver radiologists 
and a specialized vascular liver radiologist (MR) assessed and semi-quantitatively scored imaging 
characteristics of fibrosis and portal hypertension: liver nodularity and dysmorphy, size of liver 
segment 1 and 4, ascites, splenomegaly, and varices. Ascites was defined as the presence of any 
amount of free fluid in the peritoneal cavity. Splenomegaly was defined as a spleen diameter > 12 
cm. Spleen diameter was calculated as the largest spleen bipolar diameter at the splenic hilum. 
Varices were defined as the presence of dilated vessels (regardless of the size) in one of the 5 
territories of porto-systems shunting, i.e. gasto-esophageal, spleno-renal, para-umbilical or parietal, 
mesenteric or peri-rectal, and retroperitoneal. Discrimination with systemic-pulmonary shunts was 
made following  the different pathways. 
A combination of liver peripheral atrophy with hyper signal intensity on T2-weigthed imaging and 
delayed enhancement (short ‘periphery’) and subcapsular intermingled enhanced septa (short 
‘reticulation’) were scored on MRI. Apparent diffusion coefficient (ADC) and relative enhancement 
ratio (RER) were calculated on diffusion-weighted imaging, as a modification of methodology 
described before (see supplementary methods).36 All focal liver lesions were described and when 
larger than 10 mm scored on the following characteristics: signal T1 and T2 intensity, diffusion-
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weighted intensity, intensity on different contrast-enhanced phases, washout, fat content, capsule 
formation, and central scar. Alpha-fetoprotein (AFP) was measured in patients with focal liver 
lesions.  
Statistical analyses  
Continuous data are presented with mean and standard deviation (±SD), nominal data as count (n) 
and percentage (%), and ordinal or not normally distributed data with median and interquartile range 
(25th-75th percentile). Independent t-test, or non-parametric tests where applicable, were used to 
compare continuous variables. Chi-Square test was used to compare categorical variables and Mann-
Whitney U test for ordinal variables. Correlations were tested with Pearson’s correlation coefficient 
or Spearman’s Rho, depending on the level of measurement. A two-sided level of p < 0.05 was 
considered statistically significant. All statistical analyses were carried out using SPSS software 
(version 22; SPSS Inc., Chicago, Illinois, USA). 
 
Results 
Clinical characteristics  
A total of 49 patients with a Fontan physiology was referred for simultaneous cardiac and 
hepatologic screening. Eleven patients refused biopsy, so they were excluded from further analyses. 
The cohort consisted of 38 patients, prospectively assessed with the multimodality approach (see 
Flowchart). Mean age at time of screening was 27 ± 6.6 years, with 74% males. Average time after 
completion of the Fontan circulation was 21.4 ± 5.5 years. For all characteristics see Table 1.  
Based on cardiac ultrasound assessment, 21 (55%) of patients had good systolic function of the 
systemic ventricle, 15 patients (40%) had mild dysfunction and two (5%) moderate dysfunction.25  
The majority of patients were classified as NYHA I (90%) or NYHA II (10%). All patients had regular 
physical activity, but the mean VO2max, as a marker of exercise tolerance, was 25.2 ± 5.8 ml/kg/min 
corresponding with 56 ± 12% of age and gender matched healthy individuals. 26 
Patients had a median BMI of 22.2 (20.3-24.6) kg/m2 and a median alcohol consumption of 1 (0-4) 
units/week. None tested positive for hepatitis B or C. Physical examination of patients did not reveal 
any signs or symptoms suggestive for chronic liver disease. All, but one patient, were treated with 
anti-thrombotics. Eleven patients (29%) used platelet aggregation inhibitors, while 26/38 used oral 
anticoagulants (23/26 coumarin derivatives and 3/26 Direct Oral Anti-Coagulants).  
Liver histology  
All patients underwent percutaneous liver biopsy without any complications defined as severe pain, 
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bleeding, or any cause that required prolonged admission, additional diagnostic procedures, or 
treatment. Antithrombotic or anticoagulant medication could be temporarily interrupted without 
bridging. No thrombotic events occurred.  
All biopsies were of sufficient quality. There was substantial interobserver agreement on portal 
fibrosis score between both pathologists (kappa=0.747, 95% CI: 0.615-0.879), but not on sinusoidal 
fibrosis score (kappa=0.104, 95% CI: -0.226-0.434).  
The median gross architectural distortion score was 3 (2-4). Median score for portal fibrosis was 2 (2-
4) and for sinusoidal fibrosis 2 (1-2). Median CHFS was 3 (2.75-4). Eleven (29%) of patients had stage 
4; cirrhosis, on all three scores. There were no patients without fibrosis on any of the scores (Figure 
1A). Median sinusoidal dilatation was 1 (.75-2) and median portal inflammation score was 0, with 
only three patients classified as mild to moderate inflammation (score 1-2). Steatosis was absent 
from all biopsies. Median collagen proportionate area (CPA) was 22.5% (16.9-29.5). CPA correlated 
with overall architectural distortion score (Rs=0.457), portal fibrosis score (Rs=0.524) and CHFS score 
(Rs=0.419; all p<.01), but not with sinusoidal fibrosis score (Rs=0.102, p=0.541). Gross architectural 
score, portal fibrosis score and CHFS all correlated significantly with each other (Rs>.800 and p<.001). 
Key histopathological features of FALD are depicted in Figure 1B.  
For further analyses, patients were divided in two groups, based on stage of fibrosis by gross 
architectural distortion score: 16 patients (42%) had mild fibrosis (stage 1-2) and 22 (68%) had severe 
fibrosis (stage 3-4). 
 Non-invasive assessment of FALD 
1) Liver biochemistry  
Liver biochemistry did not differ between patients with mild and severe fibrosis (Table 2). To 
highlight, the majority of patients in both groups had an elevated GGT (80% of patients with mild 
fibrosis vs. 86% of patients with severe fibrosis  p=.670).  
Bilirubin was increased in 30% of patients (20% with mild fibrosis and 41% with severe fibrosis, 
p=.286). Platelets (10^09/L) were within normal range in most cases (73% in both groups). MELD-XI 
scores were similar between groups and almost all within normal range. None of the parameters 
correlated with CPA (data not shown). 
2) Serum fibrosis markers  
Median ELF score was above the threshold of 7.7 in all patients, suggesting the presence of fibrosis. 
Scores were similar between groups, median 9.03 (8.38-9.25) in mild and 9.20 (8.69-9.57) in severe 
fibrosis (see figure 2A). APRI was also comparable between groups (median 0.42 (0.35-0.53) in mild 
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and 0.44 (0.35-0.64) in severe fibrosis (p=.531)). ELF and APRI did not correlate with CPA (Rs=.242, 
p=.161 and Rs=.100, p=.555 respectively).  
3) Ultrasonography and Elastography  
Six patients with severe fibrosis (27%; five with cirrhosis and one with stage 3 on gross architectural 
score) had a heterogeneous liver aspect of the parenchyma, compared to none with mild fibrosis 
(p=.030). Median CPA was also significantly higher in patients who had a heterogeneous aspect of 
the liver on ultrasound (35% (27-37) vs. 22% (17-24), p=.026).  
Portal vein flow was similar between patients with mild and severe fibrosis, see figure 2C. Portal vein 
flow and spleen size showed a moderate correlation with CPA (Rs=-.442, p=.005 resp. Rs=.452, 
p=.004). Ultrasound and Doppler flow parameters are shown in Table 3. 
Fibroscan was successful in 36/38 patients. Median liver stiffness was 22.5 (8.8- 45.7) kPa. Liver 
stiffness was similar in mild (median 21.3 (14.3-29.1) kPa) and severe fibrotic patients (26.0 (15.1-
28.9) kPa, p=.511, see figure 2B), and did not correlate with CPA (Rs=-.015, p=.931). Liver stiffness  
did not correlate to histological grade of sinusoidal dilatation (Rs=.-079, p=.648).  
4) Advanced Imaging  
Fibrosis  
In 30/38 patients we performed an MRI, and eight patients were subjected to a CT-scan. Nodularity 
was a frequently observed feature, absent only in five patients, and was evenly distributed between 
patients with mild and severe fibrosis. Other semi-quantitative fibrosis features were also equally 
present in patients with mild and severe fibrosis (see Table 4). The combination of specific hallmarks 
of cirrhosis; an enlarged caudate lobe, atrophied segment 4 and surface nodularity were present in 
five patients: two patients with severe fibrosis (stage 3) and three patients with mild (stage 2) 
fibrosis. ADC and RER were similar between groups, and did not correlate with CPA (Rs=-.092, p=.627 
and Rs=-.006, p=.972, respectively). None of the other histological component scores correlated with 
any of the imaging parameters (data not shown). 
Assessment of portal hypertension  
Varices were present in 19 (50%) patients, ascites in 22 (58%) and splenomegaly in 7 (18%) of 
patients. A combination of all three characteristics was found in five patients (see Table 5). 8/11 
patients with cirrhosis (73%) had varices compared to 11/27 (41%) patients with a lower stage of 
fibrosis (p=.074). CPA was significantly higher in patients with varices than in patients without 
varices: median 24.2% (21.5-35.7) vs. 18.5% (14.2-24.6), p=0.015.  
Liver stiffness was similar between patients with and without varices (mean 21.4 ± 11.3 kPa and 24.1 
± 9.1 kPa, respectively; p=.391). Platelet count and platelet/spleen ratio were significantly lower in 
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the group with varices (median 153 (125-175) 10^9/L and 1177 (892-1446), respectively) than in 
patients without varices (median 174 (147-222) 10^9/L, p=.020; and 1740 (1185-2009), p=.001, 
respectively). Of note, none of the patients reported clinical events such as variceal bleeding.  
Hepatic nodules 
Thirteen  patients had several nodules smaller than 10 mm, while 13 had no nodules at all.  
Nine patients had in total 25 focal hyper-enhancing hepatic lesions larger than 10 mm (median 1 
nodule per patient, ranging from 1-7) (Table 6). The number of patients with nodules was 
comparable between patients with mild and severe fibrosis (n=3, 19% and n=6, 27% respectively, 
p=.706) and patients with or without varices (4 vs. 5 patients, p=1.000). Patients with severe fibrosis 
did have more nodules (median 4 nodules; range 1-7) than patients with mild fibrosis (all three 
patients had 1 nodule, p=.047). Delayed-phase washout was present in 9 nodules (36%) in 5 patients; 
one patient with cirrhosis (stage 4) had 4 nodules with wash-out. These lesions remained stable up to 
12 months on follow-up. Two patients with stage 3 fibrosis had 1 and 2 nodules, respectively, and 2 
patients with stage 1 and stage 2 fibrosis had one nodule.  
None of these nodules had additional ancillary features such as hyperintensity on T2 and DWI images 
or fat content. The mean AFP was  low in all patients (mean AFP 3.39 ± 1.29 ug/L).  
 
Discussion  
Key findings  
The present study demonstrates (1) the presence of severe liver fibrosis, signs of portal hypertension 
and hyperenhancing nodules in a majority of asymptomatic patients with a Fontan physiology, and 
(2) the lack of correlation between several non-invasive diagnostic tools and histological confirmed 
liver fibrosis severity. These findings indicate that non-invasive diagnosis of/screening for severe 
FALD in patients with a Fontan physiology is ineffective to accurately assess liver fibrosis. 
Screening of FALD 
There is an unmet need to diagnose and assess liver fibrosis severity with non-invasive alternatives, 
as liver biopsy carries potential complications. Our data suggests that there is no role in clinical 
practice for ELF®, routine transient elastography or conventional MRI/CT to diagnose liver fibrosis in 
Fontan physiology, since it fails to correlate with histological fibrosis severity. Ultrasound 
abnormalities, such as heterogeneous aspect of parenchyma could be indicative for severe fibrosis, 
but absence of abnormalities does not rule out severe FALD. 39-41This highlights that experiences from 
patients with other forms of liver disease (e.g. liver cirrhosis as a result of alcohol abuse, hepatitis B 
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and C) cannot be applied to the Fontan population, as interference of congestion remains an issue of 
concern in this unique physiology.39-41 
Although we encountered no complications from the biopsy itself or from interruption of 
anticoagulant therapy, we acknowledge that liver biopsy is not an attractive tool to use for follow-up. 
Thus there remains an unmet need for alternatives to ease screening and follow-up in this 
population. MRI is subject to fast and major developments, and techniques such as T1-rho mapping, 
extracellular volume calculation,42 susceptibility imaging,43 and magnetic resonance elastography 14 44 
are promising. We do stress that new techniques should be validated against histology before they 
are adopted in daily practice.   
Pathophysiology  
Although not fully elucidated, chronic passive hepatic congestion is thought to be the underlying 
mechanism that puts patients with a Fontan physiology at risk for complications of advanced liver 
disease.45 In congestive hepatopathy, venous congestion elicits a sustained wound-healing response. 
Upon histological examination, this is characteristically depicted by sinusoidal dilatation, presumably 
resulting from venous pressure elevation. Consequently fibrosis arises, with also mainly a sinusoidal 
pattern.46 Over time, injury precipitates formation of broad scars, bridging fibrosis and cirrhosis. 
Fibrosis is also generated by microthrombotic events in sinusoids and veins.47 The ubiquitous 
presence of fibrosis in all biopsies examined in this study, underlines the profound impact of the 
Fontan physiology on the liver architecture, and contrasts with that in other aetiologies such as viral 
hepatitis, where only a minority of patients will ultimately develop liver fibrosis.48 The specific 
histological pattern of sinusoidal fibrosis in combination with sinusoidal dilatation can help to 
distinguish FALD from other liver diseases, however correlation with clinical information should 
always be made to identify the definite cause of liver injury, as no pattern is unique in liver 
pathology.49 
The spectrum of FALD 
The findings from our study are consistent with the spectrum of FALD ranging from mild congestive 
hepatopathy to established cirrhosis. At 21 years after surgery, the majority of patients have 
developed advanced liver disease. Some 29% had histological evidence of liver cirrhosis and 50% had 
varices. These findings are in line with those from other Fontan cohorts, reinforcing the concept that 
liver fibrosis and portal hypertension are major extra-cardiac manifestations of Fontan physiology.19, 
21, 37, 38 
This reflects the ongoing continuum that starts postoperatively with hepatic vein congestion, which 
causes liver injury resulting in ongoing fibrogenesis.5  
To address the true risk of advanced liver disease and its complications in patients with a Fontan 
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physiology we need longitudinal data that associate presence and severity of FALD to morbidity and 
mortality. 18, 50,66 In other chronic liver diseases, such as viral hepatitis and NAFLD, fibrosis stage 
determines portal hypertensive complications HCC development and ultimately prognosis.6 If this is 
also the case in patients with a Fontan physiology needs to be further elucidated by prospective 
studies. 
Portal hypertension 
In our cohort, signs of portal hypertension were more frequently seen in patients with cirrhosis. 
Splenomegaly and portosystemic varices are uncommon in congestive hepatopathy, and are 
generally related to central venous pressure being transmitted through dilated hepatic sinusoids to 
the portal venous system. We did not perform measurements of the transhepatic pressure gradient, 
but in congestive hepatopathy and FALD values are usually normal.45, 46 The presence of varices may 
be an indication of the transformation from congestion to fibrosis.51 To what degree failure of Fontan 
physiology contributes to the onset of portal hypertension remains unknown. 
Fontan nodules 
Congestive hepatopathy is also associated with the onset of focal liver lesions. Arterialized large 
regenerative nodules or focal nodular hyperplasia (FNH) are often found in congestive 
hepatopathy.52, 53 These lesions comprise of regions of parenchyma with compromised hepatic 
venous outflow and subsequently impaired portal inflow. Parenchymal perfusion thus becomes 
reliant on arterial flow, resulting in nodular regeneration of hepatocytes. It is generally assumed that 
FNH have no malignant potential.54 On the other hand, cirrhosis is associated with an increased risk 
of hepatocellular carcinoma (HCC), and HCC has been described in young cirrhotic patients with a 
Fontan physiology.55, 56 Hyperenhancing nodules were present in ~25% of patients from our cohort, 
independent of fibrosis stage, corroborating previous findings.53, 57 Wash-out,  in the setting of 
cirrhosis, is usually  a specific feature of HCC, but in FALD may  also be present in benign lesions.53 
Specific guidelines for screening of patients with a Fontan physiology for HCC are lacking,58 but the 
value of AFP, liver-specific contrast agents, and additional ancillary features for discrimination 
between benign and potentially malignant Fontan nodules should be further explored.  
Liver function & transplantation 
Finally, liver function is an issue of concern. Liver function is defined as the ability to maintain 
bilirubin metabolism and intact coagulation, and not as the increase of transaminotransferases.59 
Liver fibrosis is an important prognostic determinant in patients with other chronic liver diseases as it 
may result in impaired liver function and increased mortality.6 It is suggested that 5-year survival in 
cirrhotic patients with Fontan physiology was dismal which in turn was due to both cardiac and liver 
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related complications.7 Clinical follow-up of patients with established liver disease is facilitated by the 
MELD (Model of End stage Liver Disease) score, prioritizing patients in need of liver transplantation.60 
Transplantation data are very limited and come from several small case series that describe 
combined heart and liver transplantation in patients with a failing Fontan physiology and liver 
cirrhosis.61-63 These show good short term results, comparable to orthotopic heart transplant. 
Nonetheless, long term results are lacking. In adjusted form, MELD-XI probably predicts cardiac 
mortality or heart transplantation better than hepatological mortality, as similar outcomes are 
observed regardless of the presence of severe fibrosis.64 In our cohort, MELD-XI scores were low. 
Strengths & Limitations 
The major strength of our study lies in the optimal identification of fibrosis in this population using a 
gold standard: histological confirmation. This allows us to interpret the observations as a result of 
either congestion, fibrosis or combined. The use of multiple invasive and non-invasive modalities for 
the same patients allows a fine comparison of the diagnostic value to detect congestion or fibrosis in 
relation to the gold standard. Previous studies investigating non-invasive alternatives to assess FALD 
lacked reference to the gold standard, hampering interpretation of results. Selection bias was limited 
since every consecutive patient was included and subjected to structural assessment. Liver fibrosis 
severity in our cohort is probably representative for the general population with Fontan physiology. 
Therefore we can answer to several important key knowledge gaps as identified by the stakeholders 
meeting of the American College of Cardiology in 2017.65 
Our study is limited by the relatively small number of patients, but on the other hand our cohort 
underwent systematic and deep characterisation of the phenotype. The study design is cross-
sectional, and exposure and outcome were simultaneously assessed. Without the presence of 
longitudinal data it is not possible to establish temporal relation between cause (Fontan physiology) 
and effect (liver fibrosis and its complications) or to assess the value of non-invasive diagnostics in 
monitoring of FALD. Longitudinal assessment of liver stiffness measurements has the potential to be 
helpful in monitoring patients with a Fontan physiology 44, but needs further confirmation.  Future 
research should focus on assessing modalities for surveillance of these patients and on 
pathophysiology and risk factors for progression of FALD.65   
Conclusion 
In conclusion, we show that cirrhosis and signs of portal hypertension are present in substantial 
proportion of patients with a Fontan physiology, and that MRI, CT, transient elastography, and serum 
biomakers are unable to accurately assess severity of liver fibrosis in this cohort. This emphasizes the 
need for prospective longitudinal follow-up studies to further assess morbidity and mortality risk and 
to search for non-invasive alternatives to diagnose and monitor FALD. 
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Figure Legends 
Study flowchart: Legend: Flowchart of number of patients referred for hepatologic screening and 
actually screened by the several modalities incorporated in screening.  
 
Figure 1A: Legend: Distribution of the assessed histological scores is displayed on the X-axis, with 
percentages of the scoring stages depicted on the Y-axis.  
Figure 1B: Legend: Legend: Exemplary photographs of histological slides from patients with FALD, 
were taken with a camera attached to a microscope and processed in a digital image analysis 
programme. Panel 1: mild sinusoidal dilatatation (stage 1). Hematoxylin-Eosin stain, objective lens 
10x. Panel 2: severe sinudoidal dilatation (stage 3). Hematoxylin-Eosin stain, objective lens 10x. Panel 
3: mild sinusoidal fibrosis, with characteristic chicken-wire pattern of staining along the dilated 
sinudoids. Sirius Red stain, objective lens 20x. Panel 4: close-up of cirrhotic liver biopsy of patient 
with FALD, showing severe sinusoidal fibrosis and dilatation (stage 3) and gross architectural 
distortion (stage 4), with broad scarring and nodular regeneration. Sirius Red stain, objective lens 
10x. 
 
Figure 2: Legend: Data points in the graphs represent individual patient data, with the line 
representing the median value in patients with mild (n=16), compared to patients with severe 
fibrosis (n=22). Panel A represents ELF scores as measured in serum, Panel B liver stiffness (in kPa) as 
measured by Fibroscan®, and Panel C portal vein flow (in cm/s) as measured with Doppler flow on 
liver ultrasonography. Missing data: ELF score is missing in 3 patients with severe fibrosis.  
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Tables  
Table 1. Patient characteristics  
 
 
Demographics  
Female gender 10/38 (26%) 
Age (years)  27 ± 6.6 
Body mass index (kg/m2) 22.2 (20.3-24.6)  
Congenital main diagnosis  
Atresia (pulmonary/tricuspidal) 18/38 (47%) 
Double-inlet Left Ventricle 11/38 (29%) 
Other*  9/38 (24%) 
Type of Fontan procedure   
Atriopulmonary connection 14/38 (37%) 
Lateral tunnel 7/38 (18%) 
Extracardiac conduit  15/38 (40%) 
Kawashima, secondary connection 
liver veins to pulmonary system 
2/38 (5%) 
Age at Fontan procedure (years) 5.0 (3.0-6.3) 
Fontan duration (years) 21.4 ± 5.5 
Medication   
Oral anticoagulants Ɨ  26/38 (68%) 
Hepatotoxic medicaƟon † 1/38 (3%) 
Legend: Data are presented as mean (SD) or median (IQR) for continuous variables and  
as n, % for categorical variables. * Other cardiac main diagnosis include: hypoplastic left  
heart syndrome (n=4), double-inlet right ventricle (n=2), double-outlet right  
ventricle (n=2), left isomerism with univentricular heart (n=1). Ɨ used anticoagulants 
are acenocoumarol (n=17), fenprocoumon (n=6), Direct Oral Anti-Coagulant (n=3)  
† one paƟent used amiodaron and quinapril. 
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Table 2. Laboratory results of patients with mild vs severe fibrosis  
 Mild fibrosis (n=16)† Severe ﬁbrosis (n=22)† p-value 
 Median (IQR) n, % abnormal Median (IQR) n, % abnormal 
 
ALT (IU/L) 28 (24-33) 1/15 (7%) 28 (23-37) 3/22 (14%) .915 
AST (IU/L) 28 (23-33) 1/15 (7%) 28 (25-35) 5/22 (23%) .551 
ALP (IU/L) 70 (54-97) 2/15 (13%) 81 (70-96) 2/22 (9%) .105 
GGT (IU/L) 58 (46-104) 12/15 (80%) 62 (49-121) 19/22 (86%) .636 
Bilirubin (mmol/L) 13 (11-19) 3/15 (20%) 16 (11-22) 9/22 (41%) .761 
Albumin (g/L) 41 (40-43) 0/13 42 (40-44) 0/21 .529 
MELD-XI score  9.44 (9.44-10.98) 1/12 (8%) 9.44 (9.44-11.08) 3/22 (14%) .873 
Legend: Data are presented as median with (IQR) and n,% of patients with an abnormal result (elevated or diminished, in 
comparison to the upper or lower limit of normal) on the corresponding test. * For APRI there is not a uniform cut-off 
available. P-values are shown for non-parametric analyses between median values of laboratory results in patients with 
mild and severe ﬁbrosis. †Missing data: In one patient with mild fibrosis no blood results were present except for ELF. 
MELD-XI score could not be calculated, because of missing creatinin values in 4 patients with mild fibrosis. In 2 patients with 
mild fibrosis missed bilirubin and albumin. Albumin was missing in 1 and ELF in 3 patients with severe fibrosis. Total number 
of patients with available blood results are stated as denominator in the row showing n,% of abnormal test results.   
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Table 3. Parameters ultrasound and Doppler flow measurements  
 Mild fibrosis (n=16) Severe fibrosis (n=22) p-value 
Ultrasound parameters    
Enhanced pattern liver  3/16 (19%) 2/22 (9%) .632 
Heterogeneous aspect parenchyma 0/16 6/22 (27%) .03 
Irregular liver surface  5/16 (31%) 1/22 (5%) .065 
VCI compliance (<50%)  15/16 (94%) 18/20 (90%) 1.000 
Spleen size (cm) 11.6 (10.3-13.0) 11.8 (10.5-13.0) .895 
Doppler Flow parameters    
Monophasic flow hepatic veins  2/16  (13) 3/22 (14%) n.a. 
Portal vein flow (cm/s) 16.5 (14.0-24.8) 16.3 (13.1-20.0) .529 
Hepatic artery flow max (cm/s) 69.4 (57.2-90.3) 65.8 (55.6-85.2) .617 
End diastolic hep artery flow (cm/s)  20.7 (14.4-33.0) 19.7 (16.8-23.8) .660 
Resistance Index  0.66 (0.58-0.84) 0.70 (0.64-0.79) .800 
Legend: Data are presented as median (IQR) for continuous variables and as n, % for categorical variables. Missing data: VCI 
compliance and resistance index could not be measured in 2 patients and end diastolic hepatic artery flow was missing in 
one patient.  
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Table 4. Radiological evaluation of fibrosis characteristics compared to histology  
 Mild fibrosis (n=16) Severe fibrosis (n=22) p-value 
Periphery* 
None 
Mild 
Marked 
 
0/11 
6/11 (55%) 
5/11 (45%) 
 
1/19 (5%) 
10/19 (53%) 
8/19 (42%) 
0.740 
Nodularity 
None 
Mild 
Marked 
 
3/16 (19%) 
6/16 (38%) 
7/16 (44%) 
 
2/22 (9%) 
9/22 (41%) 
11/22 (50%) 
0.684 
Reticulation* 
None 
Mild 
Marked 
 
0/11 
7/11 (64%) 
4/11 (36%) 
 
4/19 (21%) 
7/19 (37%) 
8/19 (42%) 
0.179 
Dysmorphy 16/16 (100%) 22/22 (100%) - 
Segment 1 
Atrophy 
Normal 
Enlarged 
 
0/16 
1/16 (6%) 
15/16 (94%) 
 
0/22 
4/22 (18%) 
18/22 (82%) 
0.374 
Segment 4 
Atrophy 
Normal 
Enlarged 
 
4/16 (25%) 
9/16 (56%) 
3/16 (19%) 
 
3/22 (14%) 
12/22 (55%) 
7/22 (32%) 
0.534 
ADC* 1.03 (0.96-1.30) 1.0 (0.96-1.04) 0.250 
RER 0.45 (0.38-0.65) 0.51 (0.41-0.61) .988 
Legend: Data are presented as median (IQR) for continuous variables and as n, % for categorical variables.  
*ADC, Periphery and reticulation characteristics can only be assessed on MRI, therefore not measured in 8  
patients (5 mild, 3 severe fibrosis).  
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Table 5. Signs of portal hypertension in patients with mild and severe fibrosis  
 Mild fibrosis (n=16) Severe fibrosis (n=22) p-value 
Varices 7/16 (44%) 12/22 (54%) 0.511 
Ascites 9/16 (56%) 13/22 (59%) 0.861 
Splenomegaly 3/16 (19%) 4/22 (18%) 1.000 
Combination of all 3* 2/16 (13%) 3/22 (14%) n.a.  
Platelets (10^09/L) 164 (137-186) 155 (136-191) .963 
Diminished platelet count (n,%) 4/15† (27%) 6/22 (27%) 1.000 
Platelet/spleen ratio 1416 (1032-1763) 1297 (1123-1745) 1.000 
VWF (%) 100 (100-100) 100 (100-105) .417 
VITRO score  63.4 (44.6-72.7) 64.9 (46.8-84.0) .421 
Legend: Data are presented as median (IQR) for continuous variables and as n, % for categorical variables. Missing data: In 
one patient no blood results were present, so platelet/spleen ratio and VITRO score could not be calculated.  
*combination of varices, ascites and splenomegaly on advanced imaging. †platelet count was missing in one paƟent with 
mild fibrosis.  
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Table 6. Features of nodules > 10mm 
25 Nodules in 9 patients  
 
Size (mm) 
10-20 mm 
>20 mm 
18.0 ±6.2 
19/25 (76%) 
6/25 (24%) 
Location 
Right hemi-liver 
Left hemi-liver 
Caudate lobe 
 
13/25 (52%) 
11/25 (44%) 
1/25 (4%) 
Signal intensity (T1-weighted) 
Hypo-intense 
Iso-intense 
Hyperintense 
 
0  
20/25 (80%) 
5/25 (20%) 
Signal intensity (T2-weighted) 
Hypo-intense 
Iso-intense 
Hyperintense 
 
4/25 (16%) 
21/25 (84%) 
0 
Diffusion-weighted*  
Hyperintense 
 
0  
Arterial phase  
Hyper-intense 
 
25/25 (100%) 
Portal phase 
Hypo-intense 
Iso-intense 
Hyperintense 
 
0  
3/25 (12%)  
22/25 (88%) 
Delayed phase 
Hypo-intense 
Iso-intense 
Hyperintense 
 
9/25 (36%) 
11/25 (44%) 
5/25 (20%) 
Washout 
Hypo-intense on portal phase 
Hypo-intense on delayed phase 
    -Hyper>iso >hypo  
    -Hyper>hyper>hypo 
No washout 
Hyperintense all phases 
 
0 
9/25 (36%) 
   -3/25 (12%) 
   -6/25 (24%) 
13/25 (52%)  
3/25 (12%) 
Other 
Fat content  
Capsule 
Central scar 
 
0 
5/25 (20%) 
4/25 (16%) 
Legend: Data are presented as mean ± SD for continuous variables and as n, % for  
categorical variables. * Diffusion-weighted images only available on MRI, missing  
data on 5 nodules.  
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Figures:  
Summarizing illustration:  
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Study flowchart  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.  
 
 
 
 
 
 
 
 
 
Liver biopsy performed 
(n = 38) 
Patients referred for hepatologic and cardiac 
screening (n = 49) 
Patients unable to 
undergo biopsy 
(n = 11) 
Ultrasound  (n = 38)  
Laboratory  (n = 37)  
Fibroscan  (n = 36) 
ELF   (n = 35)  
MRI   (n = 30) 
CT   (n = 8)   
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Figure 1. FALD histology  
Panel A: Distribution of liver histology scores  
 
 
 
Panel B: histological images of key pathological features of FALD  
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Figure 2. ELF, Liver stiffness and portal vein flow in mild vs severe fibrosis  
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Supplementary methods  
Histology 
Description histological fibrosis scores : First, the gross architectural distortion score (modified from 
METAVIR) was scored, ranging from 0 (no definite fibrosis); 1 (minimal fibrosis: no septa or rare thin 
septum); 2 (mild fibrosis: occasional thin septa); 3 (moderate fibrosis: moderate thin septa; up to 
incomplete cirrhosis) to 4(cirrhosis definite or probable).  
Second, the Fontan Fibrosis score , a score consisting of 4 components (portal fibrosis, sinusoidal 
fibrosis, sinusoidal dilatation, and portal inflammation), was scored . Portal fibrosis was scored: 0 (no 
fibrosis); 1 (enlarged, fibrotic portal tracts); 2 (periportal, or portal-portal septa but intact 
architecture); 3 (fibrosis with distorted architecture, but no obvious cirrhosis); 4 (cirrhosis, probable 
or definite). Sinusoidal fibrosis was scored: 0 (no sinusoidal fibrosis); 1 (sinusoidal fibrosis in < 1/3 
sinusoids); 2 (in 1/3-2/3 sinusoids); 3 (in > 2/3 sinusoids); 4 (cardiac cirrhosis: extensive central vein-
central vein bridging). This score also includes sinusoidal dilatation (0-3): 0 (no dilatation); 1 
(dilatation in <1/3 sinusoids); 2 (in 1/3-2/3 sinusoids); 3 (in > 2/3 sinusoids) and portal inflammation 
0-3 scale (no/mild/moderate/marked inflammation in some or all portal tracts).  
Lastly, the congestive heart failure fibrosis score (CHFS), was scored: 0 (no fibrosis); 1 (central zone 
fibrosis); 2A (central zone and mild portal fibrosis, with accentuation at central zone); 2B (at least 
moderate portal fibrosis and central zone fibrosis, with accentuation at portal zone); 3 (bridging 
fibrosis); 4 (cirrhosis).  
 
Magnetic resonance imaging protocol 
MR imaging was performed with a 3-T imager (Siemens Prisma/Skyra, the Netherlands) using a 
phased-array surface coil after 3 hours of fasting. Buscopan (1ml iv) was administered for anti-
spasmolytic effect, previous to scanning.  
The protocol included a T2-weighted single-shot sequence, a T2-weighted fast spin-echo sequence 
with spectral fat saturation, and a transverse breath-hold 3D T1-weighted fat-suppressed spoiled 
gradient-recalled echo sequence before and after dynamic injection of 0.1 mmol/kg of body weight 
(max 7.5 ml) of gadolinium chelates (Dotarem®; gadoterate meglumine) followed by a 20-mL saline 
solution flush at a rate of 2 mL/sec administered with a power injector. After the T2 haste (blanco) 
phases, the scanning of the arterial phase was initiated after bolus tracking (sufficient contrast 
uptake in a region of interest in the aorta). Arterial scanning phase lasts for 13 sec, followed after 30 
seconds by the venous phase (also 13 sec). Delayed phase was fixed at 180 seconds after intravenous 
contrast injection. A free-breathing fat-suppressed single-shot echoplanar DW MR sequence was 
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performed before contrast injection with b values of 50, 500 and 800 sec/mm2. Cardiac gating was 
not used. Sequence parameters are shown below.  
Sequence parameters 
Sequences N slices TR/TE (ms) Slice 
thickness 
(mm) 
Flip 
Angle 
(°) 
N 
concatenations 
T2-weighted haste  30 1400/87 5 160 3 
T2-weighted haste with 
spectral fat saturation  
35 1600/95 5 160 4 
T1-weighted vibe   72 3.97/ 
1.29 (TE1) 
2.52 (TE2) 
3 9 1 
Diffusion-weighted  35 5900/52 5 - 1 
 
Computed tomography protocol 
Contrast-enhanced four phase CT was performed on 320-slides multidetector CT scanners (Toshiba 
Aquilion). As preparation patients fasted for 3 hours and drank 900 mL Telebrix Gastro 45 minutes 
and 450 mL water 30 minutes pre-scanning.  
Unenhanced multidetector CT abdominopelvic images were initially obtained. Contrast-enhanced 
acquisitions were obtained following intravenous administration of Iomeprol contrast medium at 300 
mg iodine per milliliter, calculated on total body weight (ranging 120-150 ml), through an 20-gauge 
catheter in a fixed time of 30 seconds (rate 4-5 mL/sec) by a power injector, followed by a 40-mL 
saline solution flush. The late arterial phases were acquired at an empirical fixed delay of 24 seconds 
after bolus tracking, and portal venous phases after another 20 seconds (around 60-70 sec). The late 
phases were fixed at 180 seconds after contrast administration had begun. See below for the used 
scanning and reconstruction parameters:  
Scan parameters 
 
Unenhanced Arterial Venous Late 
Mode Helical Helical Helical Helical 
Collimation 80 x 0.5 80 x 0.5 80 x 0.5 80 x 0.5 
kV Auto Auto Auto Auto 
Sure Exposure (mAs) SD 17.5 SD 17.5 SD 17.5 SD 17.5 
Rotation time 0.5 0.5 0.5 0.5 
Pitch Standard Standard Standard Standard 
Scan direction Cranio-Caudal Cranio-Caudal Cranio-Caudal Cranio-Caudal 
API Inspiration Inspiration Inspiration Inspiration 
Iterative 
reconstruction 
AIDR3D 
Enhanced 
AIDR3D 
Enhanced 
AIDR3D 
Enhanced 
AIDR3D 
Enhanced 
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Reconstruction parameters 
  Axial 1   Volume 1   Multiview 1       
Unenhanced Body Axial 3 / 2.4 Body Volume 1 / 0.8         
Arterial Body Axial 3 / 2.4 Body Volume 1 / 0.8         
Venous Body Axial 3 / 2.4 Body Volume 1 / 0.8 MPR Coronal 
MPR Sagital 
3 / 2 
3 / 2 
    
Late Body Axial 3 / 2.4 Body Volume 1 / 0.8         
 
 
Calculation Relative Enhancement ratio 
The relative enhancement ratio (RER) of liver pattern between pre-contrast and delayed phase was 
calculated, as a modification of the previously described method by Feier et al.36 This ratio is based 
on signal intensity (SI) of the liver and the paraspinal muscles (to normalize the signal) on pre-
contrast and delayed (post) phase T1-weighted imaging. The following equation was used: 
RER=  
(SI liverpost/ SI musclepost) -  (SI liverpre/ musclepre )(SI liverpre/ SI musclepre) 
  
  
 
 
 
